P33.20 Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Immunotherapy revolutionized NSCLC treatment. At present, the only established predictive biomarker for I/O-therapy stratification is PD-L1 expression. However, the expression of PD-L1 is limited by heterogeneous expression and even low expressors harbor patients that respond to I/O therapy. The aim of the study is to evaluate the value of combinations of positive (Tumor Mutational Burden, PD-L1) and negative (a.o. CD73 and VISTA expression, inactivating STK11 and KEAP1 mutations) predictive markers in patients (pts) with advanced NSCLC on I/O-therapy.